Our latest articles
Kezar gets a second chance
However, data with zetomipzomib in lupus nephritis are not quite as good as they first appear.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Epizyme accepts reality
Dire market conditions combine with a loan overhang and investor desertion to force Epizyme's hand in a low-ball takeout.
Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
Sarepta loses its Momentum
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.
Karuna seeks a novel schizophrenia mechanism
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
PTC’s confirmatory Duchenne data resurrect US hopes
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.
